Jefferies: 'we can still see at least a +25-50% stock move if SRPT shows competitive/superior 6-month splicing/vHOT data'
Tweet Send to a Friend
Jefferies analyst Andrew Tsai reiterated a Buy rating and $30.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).The analyst comments "Other ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
